Clinical trial
A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of ASP5541 in Chinese Participants With Advanced Prostate Cancer
NCT07339267 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of ASP5541 in Chinese Participants With Advanced Prostate Cancer
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- January 20, 2026
- Completion date
- December 31, 2028
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic castration-resistant prostate cancer, metastatic hormone sensitive prostate cancer, prostate cancer